GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas

被引:57
|
作者
Davis, Drew G. [1 ]
Siddiqui, Momin T. [1 ]
Oprea-Ilies, Gabriela [1 ]
Stevens, Keith [1 ]
Osunkoya, Adeboye O. [1 ]
Cohen, Cynthia [1 ]
Li, Xiaoxian [1 ]
机构
[1] Emory Univ Hosp, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
Breast; GATA-3; FOXA1; Carcinoma; IHC; Urothelial; Prostatic; Mesothelioma; TMA; Unknown primary tumor; ESTROGEN-RECEPTOR; IMMUNOHISTOCHEMICAL EVALUATION; ANDROGEN RECEPTOR; CANCER; REVEALS; UTILITY; MARKER; A1;
D O I
10.1016/j.humpath.2015.09.015
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
GATA-3, a member of the GATA family of zinc-finger DNA binding proteins, and FOXA1, a member of the forkhead transcription factor family, are both associated with estrogen receptor expression. Both GATA-3 and FOXA1 are useful markers for breast carcinoma, but their expression in the different breast cancer subtypes and other neoplasms has not been thoroughly evaluated. We examined the expression of GATA-3 and FOXA1 in estrogen receptor positive, Her2/neu positive, and triple-negative breast carcinomas as well as in 10 other common carcinomas, including hepatocellular, colonic, pancreatic, gastric, endometrial (endometrioid), lung, prostatic, renal cell, urothelial, and ovarian serous carcinomas. Primary and metastatic melanomas and mesotheliomas were also evaluated. GATA-3 and FOXA1 staining of estrogen receptor positive breast carcinomas was seen in 96.6% and 96.2%, respectively. In triple-negative breast carcinomas, GATA-3 and FOXA1 staining was seen in 21.6% and 15.9%, respectively. Among the other tumors, GATA-3 staining was only seen in urothelial carcinoma (70.9%) and FOXA1 staining was only seen in prostatic (87.5%), urothelial (5.1%) carcinomas, and mesotheliomas (40.0%). In conclusion, GATA-3 and FOXA1 are excellent breast carcinoma markers; however, their utility is limited in the triple-negative subtype. The utility of FOXA.1 in diagnosing prostatic carcinoma and mesothelioma warrants further investigation. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [1] Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours
    Albergaria, Andre
    Paredes, Joana
    Sousa, Barbara
    Milanezi, Fernanda
    Carneiro, Vitor
    Bastos, Joana
    Costa, Sandra
    Vieira, Daniella
    Lopes, Nair
    Lam, Eric W.
    Lunet, Nuno
    Schmitt, Fernando
    BREAST CANCER RESEARCH, 2009, 11 (03):
  • [2] Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
    Hisamatsu, Yuichi
    Tokunaga, Eriko
    Yamashita, Nami
    Akiyoshi, Sayuri
    Okada, Satoko
    Nakashima, Yuichiro
    Taketani, Kenji
    Aishima, Shinichi
    Oda, Yoshinao
    Morita, Masaru
    Maehara, Yoshihiko
    BREAST CANCER, 2015, 22 (05) : 520 - 528
  • [3] GATA Binding Protein 3 (GATA-3) expression evaluation as prognostic factor in breast cancer and its relationship with other immunemarkers
    Tabriz, Hedieh
    Farmani, Elahe
    Nazar, Elham
    Javadi, Arezoo
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (02) : 286 - 290
  • [4] Immunohistochemical Evaluation of GATA-3 Expression in ER-Negative Breast Carcinomas
    Liu, Haiyan
    Shi, Jianhui
    Prichard, Jeffrey W.
    Gong, Yun
    Lin, Fan
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (05) : 648 - 655
  • [5] Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
    Yuichi Hisamatsu
    Eriko Tokunaga
    Nami Yamashita
    Sayuri Akiyoshi
    Satoko Okada
    Yuichiro Nakashima
    Kenji Taketani
    Shinichi Aishima
    Yoshinao Oda
    Masaru Morita
    Yoshihiko Maehara
    Breast Cancer, 2015, 22 : 520 - 528
  • [6] Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues
    Hassani, Bita
    Taheri, Mohammad
    Asgari, Yazdan
    Zekri, Ali
    Sattari, Ali
    Ghafouri-Fard, Soudeh
    Pouresmaeili, Farkhondeh
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer
    Martin, Elizabeth M.
    Orlando, Krystal A.
    Yokobori, Kosuke
    Wade, Paul A.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2021, 71 : 65 - 70
  • [8] Semiquantitative GATA-3 Immunoreactivity in Breast, Bladder, Gynecologic Tract, and Other Cytokeratin 7-Positive Carcinomas
    Clark, Beth Z.
    Beriwal, Surabhi
    Dabbs, David J.
    Bhargava, Rohit
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (01) : 64 - 71
  • [9] The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy
    Kimihiro Tanaka
    Eriko Tokunaga
    Nami Yamashita
    Yasuaki Sagara
    Yasuyo Ohi
    Kenichi Taguchi
    Shinji Ohno
    Shinji Okano
    Yoshinao Oda
    Yoshihiko Maehara
    Breast Cancer, 2017, 24 : 384 - 392
  • [10] The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy
    Tanaka, Kimihiro
    Tokunaga, Eriko
    Yamashita, Nami
    Sagara, Yasuaki
    Ohi, Yasuyo
    Taguchi, Kenichi
    Ohno, Shinji
    Okano, Shinji
    Oda, Yoshinao
    Maehara, Yoshihiko
    BREAST CANCER, 2017, 24 (03) : 384 - 392